<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987047</url>
  </required_header>
  <id_info>
    <org_study_id>2021RC01</org_study_id>
    <secondary_id>2021-A00809-32</secondary_id>
    <nct_id>NCT04987047</nct_id>
  </id_info>
  <brief_title>Evaluation of the Relevance of Pharmacogenetics in the Prescription Off Antidepressants in a Military Population</brief_title>
  <acronym>PSYGEN</acronym>
  <official_title>Evaluation of the Relevance of Pharmacogenetics in the Prescription Off Antidepressants in a Military Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of depression, anxiety disorders and post-traumatic stress disorder (PTSD) is a&#xD;
      main public health problem due to the frequency of these pathologies and the very partial&#xD;
      effectiveness of the existent therapies. These illnesses generally require the prescription&#xD;
      of several successive lines of antidepressant treatments before the treatments actually&#xD;
      become effective, leading to a several week delay during which the patient suffers from the&#xD;
      symptoms of his/her pathology and is also likely to experience the side effects of the&#xD;
      treatment.&#xD;
&#xD;
      Pharmacogenetics is an individualized prescribing modality that aims to predict the most&#xD;
      favorable treatment for a given individual based on the study of genetic variants of&#xD;
      cytochromes.&#xD;
&#xD;
      The main hypothesis of this research is that the use of pharmacogenetics in routine practice&#xD;
      in a population of military personnel requiring a first prescription of an antidepressant is&#xD;
      of interest to improve the tolerance and effectiveness of the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER) scale deleterious score ≤ 2 after 8 weeks of treatment</measure>
    <time_frame>8 weeks after antidepressant treatment initiation</time_frame>
    <description>This endpoint will allow to assess the clinical tolerance of antidepressant treatment and to compare the results between the 2 arms.&#xD;
The FIBSER scale score ranges from 0 to 18 with higher scores reflecting more deleterious side effects.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <condition>Ptsd</condition>
  <arm_group>
    <arm_group_label>Prescription with pharmacogenetics assistance</arm_group_label>
    <description>The participants randomized in this arm will received a prescription of antidepressants based on the results of pharmacogenetics analyses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prescription without pharmacogenetics assistance</arm_group_label>
    <description>The participants randomized in this arm will received a prescription of antidepressants left to the discretion of the clinician without pharmacogenetics assistance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>A blood sample will be collected at enrollment to perform pharmacogenetics analyses.</description>
    <arm_group_label>Prescription with pharmacogenetics assistance</arm_group_label>
    <arm_group_label>Prescription without pharmacogenetics assistance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Several questionnaires will be filled by the participants or by the clinicians at every study visits: Hospital anxiety depression scale (HAD), Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), Quick inventory of depressive symptomatology - self rated (QiDS), Beck's Anxiety Inventory (BAI), World Health Organization Quality Of Life (WHOQOL-BREF), EuroQol Group questionnaire (EQ5D), Frequency, intensity, burden of side effects rating (FIBSER), Udvalg for Kliniske Undersøgelser - Side Effects Rating Scale - for Patients (UKU-SERS-PAT), Clinical Global impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS).</description>
    <arm_group_label>Prescription with pharmacogenetics assistance</arm_group_label>
    <arm_group_label>Prescription without pharmacogenetics assistance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive test battery (optional)</intervention_name>
    <description>For patients participating in the ELAN ancillary study : the participants will undergo a battery of neurocognitive tests assessing vital impetus (&quot;élan vital&quot; in French).</description>
    <arm_group_label>Prescription with pharmacogenetics assistance</arm_group_label>
    <arm_group_label>Prescription without pharmacogenetics assistance</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be composed of military patients consulting as outpatients or&#xD;
        hospitalized in a psychiatric service, requiring a prescription for an antidepressant.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18 and 65 years-old;&#xD;
&#xD;
          -  To benefit from a medical follow-up in the psychiatric department of an army training&#xD;
             hospital;&#xD;
&#xD;
          -  To present a pathology requiring an antidepressant treatment and whose prescription&#xD;
             can wait 10 days;&#xD;
&#xD;
          -  To have given written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  To be currently treated with an antidepressant or antidepressant stopped less than 15&#xD;
             days ago;&#xD;
&#xD;
          -  To have one or more contraindication to the introduction of an antidepressant&#xD;
             treatment;&#xD;
&#xD;
          -  Pregnancy or breastfeeding;&#xD;
&#xD;
          -  To require a measure of constraint.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emeric SAGUIN, MD</last_name>
    <phone>143985440</phone>
    <phone_ext>+33</phone_ext>
    <email>emeric.saguin@intradef.gouv.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie BOUSSAUD, MD</last_name>
      <phone>141466298</phone>
      <phone_ext>+33</phone_ext>
      <email>marie.boussaud@intradef.gouv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Laveran</name>
      <address>
        <city>Marseille</city>
        <zip>13384</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric PAUL, MD</last_name>
      <phone>491617282</phone>
      <phone_ext>+33</phone_ext>
      <email>frederic1.paul@intradef.gouv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Bégin</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emeric SAGUIN, MD</last_name>
      <phone>143985440</phone>
      <phone_ext>+33</phone_ext>
      <email>emeric.saguin@intradef.gouv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Sainte-Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles GHEORGHIEV, MD</last_name>
      <phone>483162159</phone>
      <phone_ext>+33</phone_ext>
      <email>charles.gheorghiev@intradef.gouv.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antidepressants</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

